3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Suspended
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
32
Neoplasms
28
Colorectal Neoplasms
19
Prostatic Neoplasms
16
Lung Neoplasms
13
Leukemia, Myeloid, Acute
12
Glioblastoma
12
Stomach Neoplasms
10
Head and Neck Neoplasms
10
Carcinoma, Non-Small-Cell Lung
10
Pancreatic Neoplasms
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Melanoma
8
Glioma
8
Brain Neoplasms
8
Rectal Neoplasms
7
Carcinoma, Hepatocellular
7
Ovarian Neoplasms
6
Neoplasm Metastasis
6
Hematologic Neoplasms
6
Uterine Cervical Neoplasms
5
Polycystic Ovary Syndrome
5
Myelodysplastic Syndromes
5
Multiple Myeloma
5
Esophageal Neoplasms
5
Carcinoma, Renal Cell
5
Triple Negative Breast Neoplasms
4
Lymphoma, B-Cell
4
Lymphoma
4
Depression
4
Interventions
talazoparib
1
CX 5461
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Suspended
×
OTHER
×
Metastatic Castration Resistant Prostate Cancer (mCRPC)
×
Clear all
NCT05425862
2023-12-11
REPAIR
Peter MacCallum Cancer Centre, Australia
Phase 1
Suspended
48 enrolled